|
Accelerating NDD Biomarker Development to The panel will explore the full arc of diagnostic biomarker development in conjunction with drug development in neurodegenerative diseases (NDDs)—from early discovery to clinical adoption—emphasizing both the scientific opportunities and systemic challenges unique to this therapeutic area. Through case studies, insights from current experiences with biomarker development in NDD, and strategic foresight, we’ll unpack how to responsibly accelerate innovation while building a sustainable path to impact. Date: Tuesday, December 2, 2025 Panelists: Nick Ashton, PhD Banner Health Alicia Algeciras, PhD Mayo Clinic, Rochester, MN Oskar Hansson, MD, PhD Eli Lilly Vice President for Neurodegenerative Diseases, Early Phase Clinical Development, and Imaging development Michael Hodsdon, MD, PhD Eli Lilly Vice President for Clinical Diagnostic Laboratory Chris Bird, DPhil Chief Medical Officer, Beckman Coulter Moderator: Joachim Reischl, PhD Vice President, Innovation, Danaher Diagnostics A light breakfast will be served.* *MA/VT physicians: this meal is provided by Beckman Coulter Diagnostics and Danaher in connection to an educational presentation about neurodegenerative disease biomarkers. The approximate value of the meal is $10 per person. By accepting this meal, you acknowledge this disclosure and that Beckman Coulter Diagnostics and Danaher may be required to report this transfer of value to state and federal transparency programs. If you would like to opt out, please notify a team member. (责任编辑：) |